
Please try another search
For investors seeking momentum, SPDR S&P Biotech (NYSE:XBI) ETF XBI is probably on the radar now. The fund just hit a 52-week high and is up about 45.5% from its 52-week low price of $64.38/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:
XBI in Focus
XBI focuses on the biotechnology segment of the U.S. market and offers equal-weight exposure across stocks. It is spread across various market spectrums, with 65% allocated to small caps, 20 to mid caps and the rest to large caps. The fund charges investors 35 basis points a year in fees (see: all the Healthcare ETFs here).
Why the Move?
The biotech corner of the broad healthcare sector has been an area to watch lately, given the astounding performance at the start of the fourth quarter. A slew of positive news, including study results, regulatory backdrop and deal activities, and better-than-expected corporate earnings have fueled the rally in the sector. Additionally, uncertainty over the trade deal added to the positives given that the sector is non-cyclical in nature, which provides a defensive tilt to the portfolio.
More Gains Ahead?
Currently, XBI has a Zacks ETF Rank #2 (Buy) with a High risk outlook, suggesting continued outperformance in the months ahead. Further, many of the segments that make up this ETF have a strong Zacks Industry Rank. So, there is definitely some promise for those who want to ride this surging ETF a little further.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
SPDR S&P Biotech ETF (XBI): ETF Research Reports
Original post
Zacks Investment Research
Two weeks ago, the rumor mill ramped up again about the potential restructuring of Intel Corporation (NASDAQ:INTC). The probing balloons centered around Taiwan Semiconductor...
More than a century ago, then-Representative William McKinley pursued an aggressive tariff strategy that sought to protect American industry and reduce reliance on foreign...
Early in 2025, value stocks emerged as a popular choice among investors seeking market-beating returns. However, factor-based investing strategies can be notoriously difficult to...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.